PULIKE(SH:603566)2020-10-28 16:00Financial Performance - Net profit attributable to shareholders was CNY 160,471,917.44, representing an increase of 68.79% year-on-year[17]. - Operating income for the period was CNY 639,601,996.04, reflecting a growth of 38.28% compared to the same period last year[19]. - Cash flow from operating activities reached CNY 149,050,745.91, up 109.41% year-on-year[17]. - The revenue from pig vaccines was CNY 170,972,778.43, an increase of 128.71% compared to the previous year[19]. - The revenue from poultry vaccines and antibodies was CNY 260,249,801.64, showing a growth of 23.18% year-on-year[19]. - The company reported a net profit excluding non-recurring gains and losses of CNY 125,439,659.38, up 82.73% year-on-year[17]. - Basic earnings per share rose to CNY 0.51, a 70.00% increase from the previous year[17]. - The company's net profit for the first three quarters of 2020 was ¥647,434,110.71, compared to ¥470,939,716.89 in the same period of 2019, reflecting a growth of approximately 37%[45]. - The net profit attributable to shareholders for Q3 2020 was ¥40.45 million, up 35% from ¥29.99 million in Q3 2019[52]. - The total profit for Q3 2020 was ¥48.32 million, compared to ¥34.18 million in Q3 2019, reflecting a growth of 41%[52]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,881,525,302.79, a decrease of 1.26% compared to the end of the previous year[17]. - Total liabilities increased to ¥254,809,545.03 from ¥247,417,954.12[37]. - Owner's equity remained stable at ¥321,496,000.00[37]. - Accounts receivable increased by 54.68% to ¥198,858,360.24 due to higher operating income[27]. - Other receivables decreased by 86.12% to ¥4,538,165.91 primarily from the recovery of loans by a subsidiary[27]. - Construction in progress rose by 56.66% to ¥49,243,116.46 due to increased investment in construction projects[27]. - Other non-current assets increased by 107.17% to ¥70,325,773.36 mainly from prepayments for engineering equipment[27]. - Total assets as of September 30, 2020, amounted to ¥1,658,435,872.24, a decrease from ¥1,768,603,489.29 at the end of 2019[43]. - The total liabilities as of September 30, 2020, were ¥162,767,740.09, down from ¥168,847,352.59 at the end of 2019[45]. - The company reported a total equity attributable to shareholders of ¥1,495,668,132.15, down from ¥1,599,756,136.70 at the end of 2019[45]. Cash Flow - Cash received from operating activities increased by 108.60% to ¥74,322,390.02 due to loan recoveries and increased government subsidies[30]. - Cash inflow from operating activities totaled CNY 664,903,082.43, an increase from CNY 488,878,915.40 in the same period last year, marking a growth of about 36%[59]. - Cash outflow from operating activities was CNY 515,852,336.52, compared to CNY 417,700,979.10 in the previous year, representing an increase of approximately 23.5%[63]. - The net cash flow from operating activities was CNY 149,050,745.91, significantly higher than CNY 71,177,936.30 in the same quarter of 2019, indicating an increase of about 109%[63]. - Cash flow from investment activities showed a net outflow of CNY 39,395,366.07, an improvement from a net outflow of CNY 169,443,698.40 in the previous year[63]. Operational Metrics - The weighted average return on net assets increased by 4.01 percentage points to 9.84%[17]. - Total operating revenue for Q3 2020 reached ¥225,675,942.92, a significant increase from ¥151,357,226.59 in Q3 2019, representing a growth of approximately 49%[45]. - Total operating costs for Q3 2020 were ¥198,613,854.26, up from ¥121,728,772.78 in Q3 2019, indicating an increase of about 63%[45]. - The company's operating revenue for Q3 2020 was approximately ¥117.96 million, a 39% increase from ¥84.85 million in Q3 2019[55]. - The company's basic earnings per share for Q3 2020 was ¥0.51, an increase from ¥0.30 in Q3 2019[54]. Research and Development - Research and development expenses in Q3 2020 reached ¥37.20 million, significantly higher than ¥10.62 million in Q3 2019, indicating a focus on innovation[55]. Financial Management - The financial expenses for Q3 2020 were reduced to -¥105.83 thousand from -¥1.59 million in Q3 2019, showing improved financial management[55]. - The company noted a significant adjustment in the financial statements due to the implementation of new accounting standards[77].